- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Strategies for Clinicians When Developing Protocols for Managing ARIA
Panelists discuss how developing effective management protocols for amyloid-related imaging abnormalities (ARIA) requires implementing robust baseline and follow-up MRI monitoring schedules, establishing clear symptom recognition guidelines, creating severity-based management algorithms, ensuring rapid radiological assessment capabilities, preparing standardized response plans for different presentations of amyloid-related imaging abnormalities (ARIA), educating patients and caregivers on warning signs, and maintaining close multidisciplinary collaboration between neurologists, radiologists, and infusion staff.
EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease
EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection
EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease
EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA
EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
EP: 18.Final Thoughts Alzheimer Disease Care
Video content above is prompted by the following:
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
